Provided by Tiger Trade Technology Pte. Ltd.

Evaxion Biotech A/S

3.31
+0.03000.91%
Post-market: 3.22-0.0900-2.72%19:51 EDT
Volume:540.83K
Turnover:1.79M
Market Cap:27.48M
PE:-2.41
High:3.45
Open:3.37
Low:3.12
Close:3.28
52wk High:12.15
52wk Low:2.52
Shares:8.30M
Float Shares:5.53M
Volume Ratio:0.27
T/O Rate:9.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3718
EPS(LYR):-1.2027
ROE:-109.86%
ROA:-25.97%
PB:2.88
PE(LYR):-2.75

Loading ...

Company Profile

Company Name:
Evaxion Biotech A/S
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
46
Office Location:
Dr. Neergaards Vej,5th Floor,Horsholm,Capital Region of Denmark,Denmark
Zip Code:
2970
Fax:
- -
Introduction:
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Directors

Name
Position
Helen Tayton Martin
Independent Director and Chief Executive Officer
Marianne Sogaard
Chairman and Independent Director
Lars Holtug
Independent Director
Lars Staal Wegner
Independent Director
Roberto Prego
Independent Director

Shareholders

Name
Position
Helen Tayton Martin
Independent Director and Chief Executive Officer
Birgitte Rønø
Chief Scientific Officer, Chief Operating Officer
Thomas Frederik Schmidt
Chief Financial Officer
Andreas Holm Mattsson
Chief AI Officer